n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr
SUFENTANIL CITRATE
CAS: 60561-17-3
Molecular Formula: C28H38N2O9S
n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr - Names and Identifiers
n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr - Physico-chemical Properties
| Molecular Formula | C28H38N2O9S |
| Molar Mass | 578.68 |
| Melting Point | 96.60C |
| Flash Point | 9℃ |
| Solubility | H2O: soluble1mg/mL, clear |
| Appearance | powder |
| Color | white to beige |
| Storage Condition | -20°C Freezer |
n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr - Risk and Safety
| Risk Codes | R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed. R39/23/24/25 - R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed. R11 - Highly Flammable |
| Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S27 - Take off immediately all contaminated clothing. S28 - After contact with skin, wash immediately with plenty of soap-suds. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S36/37 - Wear suitable protective clothing and gloves. S16 - Keep away from sources of ignition. S7 - Keep container tightly closed. |
| UN IDs | 3249 |
| WGK Germany | 3 |
| HS Code | 2934910000 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
| Toxicity | LD50 intravenous in dog: 14100ug/kg |
n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr - Clinical observation of propofol combined with midazolam and Sufentanil Citrate for painless gastroscopy
from Wanfang Medical
Author:
Abstract:
objective to observe the effect of propofol combined with midazolam and Sufentanil Citrate for painless gastroscopy. Methods 200 patients with American Society of Anesthesiologists (ASA) grade 1-2 who needed gastroscopy and treatment were randomly divided into two groups, group Ⅰ received intravenous injection of Sufentanil Citrate 0.1 μg/kg,1~2min after slow intravenous infusion of propofol 1~2 mg/kg; Group Ⅱ received intravenous injection of midazolam 1mg, sufentanil Citrate 0.1 μg/kg,1~2min after slow intravenous infusion of propofol 1~2 mg/kg. When the patient's consciousness disappeared, gastroscopy and treatment were started, and whether to add propofol was decided according to the limb activity and operation time until the end of gastroscopy and treatment. Results in group Ⅱ, 94 cases were completely painless, 6 cases appeared limb movement due to gastroscopy treatment time more than 10min, additional propofol 20~40mg was quiet; except for one patient who had respiratory depression during the operation, which was relieved quickly after holding up the jaw and pressurizing the mask to oxygen. There were mild fluctuations in blood pressure and heart rate during the operation, and the vital signs of the other patients were stable. The effect of group Ⅱ was better than that of group Ⅰ. Conclusion propofol combined with midazolam and Sufentanil Citrate for painless gastroscopy and treatment is a safe and effective ideal anesthesia method.
expand
Key words:
propofol; Midazolam; sufentanil Citrate; Painless gastroscopy
DOI:
10.3969/j.issn.1006-4931.2010.23.042
cited:
year:
2010
Last Update：2024-01-02 23:10:35
n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr - Clinical observation of Sufentanil Citrate for anesthesia induction
from VIP Journal Professional Edition
Author:
Li Yong-jun , Jin Xuehua , min Red Star
Abstract:
objective to investigate the efficacy and safety of sufentanil for anesthesia induction. Methods 60 ASA I-II patients with general anesthesia were randomly divided into sufentanil 0.3 μg/kg(S group). And fentanyl 3 μg/kg group (Group F), 30 cases in each group. The systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) were observed 1min before anesthesia induction, 2min after anesthesia induction, 1,2,3,5min after tracheal intubation, heart rate (HR). Results (1) after anesthesia induction, SBP,DBP,MAP,HR of the two groups showed a downward trend, and the difference was statistically significant (P0.05), MAP and HR were higher than those in Group F, but the difference was not statistically significant (P0.05).(2) the SBP,DBP,MAP and HR of the two groups increased 1min after tracheal intubation, and there was no significant difference compared with the basic value (P0.05), compared with before induction of anesthesia, the difference was statistically significant (P0.05).(3) SBP,DBP,MAP and HR at each time point after intubation in group S were higher than those in Group F, but the difference was not statistically significant (P0.05).(4) in group S, 4 cases of cough occurred after injection, but the degree was not serious. Conclusion as fentanyl, 0.3 μg/kg Sufentanil has little effect on hemodynamics after anesthesia induction, and can reduce the circulatory stress response caused by tracheal intubation, however, attention should be paid to the sequence and speed of administration.
expand
Key words:
induction of anesthesia; Sufentanil; Fentanyl
DOI:
10.3969/j.issn.1001-5949.2008.12.046
cited:
year:
2008
Last Update：2023-08-16 22:09:50
n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr - A method for the detection of Sufentanil Citrate synthetic raw materials and impurities [patent]
from Baidu Library
patent type:
invention patent
Application (patent) number:
CN201410673316.7
application date:
20141121
Public/Announcement Number:
CN104374858A
Public/announcement date:
20150225
applicant (patent):
Yichang Renfu Pharmaceutical Co., Ltd.
inventor:
Li Zhenzhou , Wang Wen , Lijun Zhong , paorong , Tian Jun , Zheng Wei
National and provincial code:
CN420502
Abstract:
The invention provides a detection method for Sufentanil Citrate synthetic raw materials and impurities, which provides retention time to determine the types of impurities by gas chromatography, and determines the content of impurities by area normalization method. Specifically, the standard solution and the mixed solution of the standard solution are injected separately, and the standard solution of each substance is subjected to chromatographic analysis; Then the sample is injected and the chromatogram is recorded, comparing the retention time of impurities on the chromatogram with the retention time of standard samples, the impurities are qualitative, and then the area normalization method is used to quantify the impurities according to the peak area of each related substance, qualitative and quantitative detection of synthetic raw materials and impurities. This method is simple and provides a good guarantee for the control of impurities in Sufentanil Citrate products.
Last Update：2023-08-16 22:09:50
n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr - New crystal form of Sufentanil Citrate and preparation method thereof
Application (patent) number:
201510896485
applicant (patent):
Jiangsu Enhua Pharmaceutical Co., Ltd.
inventor:
Hao Chao , Chen Liang , Kingdom , Wang Hui , Segment , Shi Chongjing , Zhang Gui-Sen
Abstract:
The invention relates to a type III crystal of Sufentanil Citrate and a preparation method thereof. The Sufentanil Citrate type III crystal obtained by the present invention significantly improves the solubility, significantly shortens the dissolution time, and has good stability.
Last Update：2023-08-16 22:09:50
Supplier List
View History
n-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)-propionanilidcitr
2-(4-Methoxyphenyl)-3-nitroimidazo[1,2-a]pyrimidine
137941-45-8
imidazo[1,2-A]pyridine-8-Carboxylic acid
351154-78-4
4-Piperidinecarboxamide, 1-(methylsulfonyl)-N-(4-phenoxyphenyl)-
perfluorooctanenitrile
(4S,5S)-4,5-Di(aMinoMethyl)-2,2-diMethyldioxolane dihydrochloride
HUMAN MCP-1
Cromophene
2-(4-Methoxyphenyl)-3-nitroimidazo[1,2-a]pyrimidine
137941-45-8
imidazo[1,2-A]pyridine-8-Carboxylic acid
351154-78-4
4-Piperidinecarboxamide, 1-(methylsulfonyl)-N-(4-phenoxyphenyl)-
perfluorooctanenitrile
(4S,5S)-4,5-Di(aMinoMethyl)-2,2-diMethyldioxolane dihydrochloride
HUMAN MCP-1
Cromophene